Autism spectrum disorder (ASD) is a complex neurodevelopmental condition with a strong genetic basis.
Introduction
Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by impaired social interaction and communication, as well as repetitive behavior. While its etiology is complex, ASD has a strong genetic basis (1-3). The role of de novo mutations in ASD has been firmly established through candidate gene (4, 5), whole exome (6-9), and whole genome sequencing studies (10, 11) . Although the list of risk genes implicated by de novo mutations is growing, it is still very likely far from complete, with an estimated full set of ASD genes ranging from several hundred to more than 1,000 (9). In the search for additional de novo mutations, sequencing studies continue to be an important approach, but the current sequencing cost is still very high, especially for large samples. As an alternative strategy, advanced analytical approaches, which leverage previously implicated genes and prior knowledge, have the potential to enhance risk gene discovery in an efficient and cost-effective manner.
We used machine learning methods to predict autism risk genes from their spatiotemporal expression signatures, network topology features, gene-level constraint metrics, and other general gene features. We applied four machine learning methods ranging from ones that are regression based [logistic regression and support vector machines (SVM) with Gaussian kernel] to others that are tree based (random forest and boosted trees). The optimal tuning parameters in each model were selected by a nested grid-search, and model performances were evaluated by five-fold cross validation (CV) on training data. The prediction accuracy was measured by the receiver-operator (ROC) curve and the area under the receiveroperator curve (AUC) on the hold-out set for each fold of the CV.
Based on the average prediction accuracy over five folds, the random forest model was selected as the optimal algorithm, and the corresponding prediction models were stored to predict over 17,000 unlabeled genes, which had both spatial-temporal expression signatures and constraint metrics available. Each gene was assigned a risk score indicating its likelihood of being involved in autism. The risk score was predicted as the average of scores from the five prediction models that emerged from each CV. For each labeled gene, the risk score was obtained by the prediction model that left the gene held out of the set in the CV.
Autism risk gene validation using differential gene expression evidence
Based on our gene ranking system, we classified genes into risk and non-risk genes using a threshold of risk score of 0.2, which gave the highest prediction accuracy on training data. Genes with a risk score higher than the threshold were predicted as risk genes and the remaining genes were predicted as non-risk genes. We validated the classification performance by examining whether our predicted risk genes show differential gene expression evidence for ASD. Specifically, we obtained differential gene expression summary statistics (beta and p-values) for ASD from RNA-Seq datasets for four major cortical lobes (frontal, temporal, parietal, and occipital) and their average, as well as the summary statistics for inflammatory bowel disease (IBD), a non-psychiatric disorder that we employed as a negative control (32) . We used simulation-based approach to estimate the enrichment statistics of predicted risk genes in differential gene expression evidence. We first generated a background distribution from random gene sets, while matching for gene size found in predicted risk genes. The enrichment fold was estimated by the ratio of the observed number of risk genes with differential gene expression evidence (p < 0.05) to the average number of that from random gene sets. The p-value for enrichment was then the proportion of random gene sets with the same or a greater number of genes with differential gene expression evidence, as compared to the number found for predicted risk genes. To investigate whether the enrichment of differential gene expression evidence was specific to ASD, we also performed the same enrichment analysis for IBD.
Autism risk gene validation in independent sequencing studies
We further evaluated our gene ranking system utilizing genes targeted by de novo LoF mutations from two independent studies, including one that performed whole exome sequencing of 2,517 families in the Simons Simplex Collection (SSC) cohort (9) and another that performed whole genome sequencing of the MSSNG cohort (10). For the SSC cohort, after excluding genes not included in BrainSpan, we compiled a list of 27 recurrent LoF de novo mutations in probands, 346 singleton LoF de novo mutations in probands, and 170 LoF de novo mutations in the unaffected siblings as negative controls. From the study of the MSSNG cohort, we created a list of 212 de novo LoF mutations in probands, 58 statistically significant de novo LoF or missense mutations, and 18 statistically significant de novo LoF or missense mutations that were not previously reported. For each of the six gene lists, we tested whether a larger proportion of genes were observed in the first decile of our gene ranking system than expected using a binomial test. The expected proportion (0.166) was determined using the percentage of genes with synonymous de novo mutations in the unaffected siblings of the SSC cohort.
Gene Ontology enrichment analysis
We performed Gene Ontology (GO) enrichment analysis to examine whether predicted risk genes were clustered into specific biological processes. Fisher's exact test was used to test the enrichment of risk genes in GO terms compared to non-risk genes. GO terms were chosen from the GO ontology of biological processes in MSigDB (v5.2) (33). To facilitate interpretation of the results, we included 2,758 GO terms that overlapped at least 20, but not more than 2,000 genes with our tested genes. Bonferroni correction was applied for multiple testing correction. Because GO terms were often highly overlapping in genes, we used hierarchical clustering to group significant gene sets into clusters based on similarity of their gene profiles (34). We first defined a gene overlapping matrix by counting the number of overlapping genes for each pair of gene sets. The Pearson correlation coefficient R was then calculated for each pair of gene sets based on their overlap profiles. The distance matrix for hierarchical clustering was then 1 െ ܴ 1 0 being ASD risk genes. We also compared the enrichment of candidate genes in the first decile of different gene scoring systems.
Results

Genome-wide prediction of autism risk genes
We visualized gene expression patterns for 1,084 training genes across various regions and developmental stages of human brain ( Supplementary Figure 1 ). There was a trend for known autism risk genes (left gene panel, red rows) to have higher expression levels than non-risk genes (left gene panel, blue rows).
We further tested expression level differences between known risk and non-risk genes for each specific brain region and developmental stage ( Figure 1 ). The known autism risk genes showed significantly higher expression levels on average than non-risk genes for all tested brain regions and developmental stages (p < 0.05). Of note, the difference was stronger for early-to-middle prenatal stages, ranging from 12 to 21 post-conceptional weeks (pcw).
We compared known autism risk and non-risk genes in their sensitivity to mutational changes and other gene features. As shown in Supplementary Figure 2 , compared to non-risk genes, autism risk genes were more intolerant of missense (mis_z, p = 7×10 -16 ) and LoF mutations (lof_z, p = 2×10 -23 ; pLI, p = 2×10 -22 ), were less likely intolerant of homozygous, but not heterozygous LoF variants (pRec, p = 5×10 -21 ), and had a lower probability of being tolerant of both heterozygous and homozygous LoF variants (pNull, p = 3×10 -24 ). Autism risk genes had longer coding base pairs (p = 4×10 -29 ), a higher probability of mutation across the transcript (mu_syn, p = 1×10 -16 ; mu_mis, p = 2×10 -18 ; mu_lof, p = 4×10 -19 ), and a larger number of rare synonymous or missense variants (n_syn, p = 4×10 -16 ; n_mis, p = 1×10 -6 ).
We compared the prediction accuracy of four machine learning algorithms using five-fold CV. The random forest model achieved the best prediction accuracy for autism risk genes with an AUC of 0.88 1 2
with de novo LOF mutations in the unaffected siblings (p = 0.55). Similarly, for risk genes identified from the MSSNG cohort, we found significant enrichment for all three gene lists, including the de novo LOF mutations in probands (28%, p = 2.8 × 10 -5 ), the 58 genes that reached genome-wide significance (74%, p = 6.0 × 10 -22 ), and the 18 novel genes (56%, p = 0.0002).
Gene Ontology enrichment analysis
We conducted GO enrichment analysis to examine whether predicted risk genes were clustered into specific biological processes. The full results of this analysis are shown in Supplementary Table 1 . There were 276 GO terms that remained significant after Bonferroni correction (p corrected < 0.05). Significant GO terms were grouped into five major clusters using hierarchical clustering (Supplementary Figure 5 ). These clusters included GO terms related to neuronal signaling (black), neurogenesis (red), chromatin remodeling (blue), transcriptional regulation (yellow), and protein processing (orange). Table 2 shows details for the top 10 enriched GO terms that were particularly interesting, as they included GO terms involved in ionotropic glutamate receptor signaling, motor neuron axon guidance, regulation of RNA alternative splicing, and protein dealkylation.
Comparison with other ranking systems
We compared the performance of our ranking system (RF, random forest) with five other gene scoring systems in their ability to rank labeled or unlabeled genes. Our ranking system outperformed the other scores on classifying labeled genes, as it displayed the highest AUC value 0.88 (Supplementary Figure 6 ).
When we examined the rank of an independent set of 173 autism candidate genes, our method again outperformed other methods, because our method had the smallest median ranking (indicating the greatest likelihood of the set containing autism risk genes) ( Supplementary Figure 7) . We further compared the enrichment of 173 candidate genes in the first decile of each gene ranking system ( Figure 6 ). We observed the highest proportion of candidate genes in the first decile of our ranking system (50%), which was higher than the ExAC score (45%), Sanders TADA score (43%), Iossifov probability score (39%), Krishman probability score (38%), and Zhang D score (30%). In summary, using both labeled and unlabeled genes, we showed that our method improved the performance of ranking ASD candidate genes.
The role of highest-ranked genes in ASD
We examined the function and the role of our highest-ranked genes (top ten) in ASD (table 1) . Among the top ten ranked genes, five have been reported to be involved in ASD (HERC1, NBEA, ATRX, FBXO11, and TCF20). We did not find previous direct association evidence with ASD for the other five genes (CAND1, ZYG11B, DOCK3, XPO7, and MYCBP2), suggesting these are potentially novel candidates.
Three of these genes in particular stood out (DOCK3, MYCBP2, and CAND1) for their known involvement in neuronal development. In addition, among the top ten ranked genes, five were related to the ubiquitination pathway (HERC1, CAND1, ZYG11B, FBXO11, and MYCBP2), indicating the role of protein ubiquitination pathway in ASD. Interestingly, all, but three of top ten ranked genes show reduced gene expression in ASD across four cortical lobes (p < 0.05) (Supplementary Table 3 ). The strongest differential gene expression evidence was observed for DOCK3 (p=0.00025). The lack of difference in gene expression of the three genes may be due to their lower expression postnatally, especially for TCF20
( Supplementary Figure 8 ).
Discussion
A number of methods have been developed for inferring ASD risk genes. Although they employ differing computational methodologies, conceptually, most methods were built upon the concept of guilt-byassociation, using the assumption that risk genes are functionally related. Theoretically, ASD risk genes should exert their effects at specific developmental stages in specific brain tissues or cell types that are critical to disease development. However, most existing methods have not considered the spatial and temporal patterns of gene relationships during brain development. In addition, gene-level constraint metrics, such as loss of function intolerance, have been used to prioritize ASD candidate genes, but no studies have quantitatively examined their potential for predicting ASD genes. To our knowledge, the current study represents the first method that explicitly uses human brain spatiotemporal gene expression features and gene-level constraint metrics for predicting ASD genes. Using labeled gene sets, we have demonstrated that ASD genes exhibit unique spatiotemporal gene expression patterns compared to nonrisk genes. The gene-level constraint metric features are complementary to gene expression features. A combination of both types of features achieves the highest accuracy in predicting ASD genes. We have demonstrated the validity of our method through extensive validations using independent sets of risk genes and differential gene expression evidence. We have further shown the superior performance of our ranking system over several other state-of-the-art ranking systems.
We explored the potential role of the top ranked genes in ASD risk. The gene HERC1, which encodes a protein that is a probable E3 ubiquitin-protein ligase, was assigned the highest probability for conferring ASD risk. Indeed, multiple lines of evidence indicate a role for HERC1 in ASD: 1) it was reported that HERC1 mutations caused intellectual disability and facial dysmorphism in two Colombian siblings (37);
2) A nonsense variant in HERC1 was associated with intellectual disability, megalencephaly, thick corpus callosum and cerebellar atrophy (38); 3) importantly, mutations in HERC1 were reported to be associated with ASD in an exome sequencing study (39). Another notable gene in our top list was TCF20 (ranked seventh), which encodes a transcription activator. Intriguingly, TCF20 was one of the highest ranking candidate autism risk genes (category 2) according to the most recent version of the SFARI Gene resource. Mutations in TCF20 were also implicated in Phelan-McDermid syndrome (40), developmental disorders (41), and schizophrenia (42). Our ranking system also successfully predicted another ASD gene FBXO11 (ranked sixth). FBXO11 was prioritized as a strong ASD candidate gene (43), and was recently reported to be associated with a variable neurodevelopmental disorder (44). Additionally, mutations in another two genes, NBEA1 and ATRX, ranked fourth and fifth in our analysis, have also been identified with ASD according to SFARI Gene resource.
Our ranking system also highlighted some potential novel candidate genes that may deserve further investigation. Three genes, CAND1, DOCK3, and MYCBP2, ranked second, eighth and tenth, are all involved in neuronal development. To our knowledge, direct genetic links between these genes with ASD have not been found. CAND1 encodes an essential regulator of Cullin-RING ubiquitin ligases that play a critical role in ubiquitination and protein degradation (45). Of note, the ubiquitination pathway has been implicated in neuronal function and brain disorders, including ASD (46). DOCK3 encodes dedicator of cytokinesis 3, which induces axonal outgrowth in the central nervous system. DOCK3 has been associated with Alzheimer disease (47), epilepsy (48), intellectual disability (49), and attention deficit hyperactivity disorder (50). MYCBP2 encodes an E3 ubiquitin-protein ligase that plays a role in axon guidance and synapse formation in the developing nervous system. MYCBP2 has been implicated in acute lymphoblastic leukemia and a rare inherited vision defect (51, 52). We have provided the whole list of ranked genes with their probability scores in Supplementary Table 2 . Researchers can further explore the top-ranked genes or genes of their own interest.
Our study not only provides hundreds of new ASD candidate genes with strong evidence for involvement
in ASD, but also shows that the predicted risk genes are indeed biologically meaningful and are clustered around biological processes relevant to ASD. GO enrichment analysis demonstrated that the predicted risk genes were enriched in GO terms related to neuronal signaling, neurogenesis, chromatin remodeling, and histone modification, all of which are important biological processes implicated in ASD. In addition, among our top ten ranked genes, we found that five were related to the ubiquitination pathway (HERC1, CAND1, ZYG11B, FBXO11, and MYCBP2), which is consistent with the significant enrichment of protein ubiquitination process in our GO enrichment analysis (GO_PROTEIN_UBIQUITINATION , p corrected = 9 × 10 -6 ), supporting the merging role of ubiquitin signaling in ASD (46, 53) . Our analyses also highlighted other biological mechanisms that may underlie ASD. For example, there is evidence for roles of RNA In summary, our study has demonstrated that human brain spatiotemporal gene expression patterns and gene-level constraint metrics predict ASD risk genes. Our gene ranking system provides a useful resource for prioritizing ASD candidate genes. 2 T  a  c  h  i  N  ,  H  a  s  h  i  m  o  t  o  Y  ,  M  a  t  s  u  o  k  a  M  .  M  O  C  A  i  s  a  n  i  n  t  e  g  r  a  t  o  r  o  f  t  h  e  n  e  u  r  o  n  a  l  d  e  a  t  h  s  i  g  n  a  l  s  t  h  a  t  a  r  e   a  c  t  i  v  a  t  e  d  b  y  f  a  m  i  l  i  a  l  A  l  z  h  e  i  m  e  r  '  s  d  i  s  e  a  s  e  -r  e  l  a  t  e  d  m  u  t  a  n  t  s  o  f  a  m  y  l  o  i  d  b  e  t  a  p  r  e  c  u  r  s  o  r  p  r  o  t  e  i  n  a  n 
Figure legends
Figure 1. Gene expression difference between ASD risk and non-risk genes in the spatiotemporal development of human brain. Each cell in the heat map represents the expression level difference (ttest) in a specific brain region (column) and development stage (row). The intensity of color represents the log-transformed p-value from a t-test. The brain regions and stages without gene expression data are marked as black. 
